CN105733880A - 一种以榛子粕为原料酿制的复合榛子酒 - Google Patents
一种以榛子粕为原料酿制的复合榛子酒 Download PDFInfo
- Publication number
- CN105733880A CN105733880A CN201610207655.5A CN201610207655A CN105733880A CN 105733880 A CN105733880 A CN 105733880A CN 201610207655 A CN201610207655 A CN 201610207655A CN 105733880 A CN105733880 A CN 105733880A
- Authority
- CN
- China
- Prior art keywords
- wine
- coryli heterophyllae
- semen coryli
- hazelnut
- fermentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000723382 Corylus Species 0.000 title abstract description 12
- 235000007466 Corylus avellana Nutrition 0.000 title abstract description 12
- 235000001543 Corylus americana Nutrition 0.000 title abstract description 11
- 235000012054 meals Nutrition 0.000 title abstract description 9
- 239000002131 composite material Substances 0.000 title abstract 5
- 108091007734 digestive enzymes Proteins 0.000 claims abstract description 33
- 102000038379 digestive enzymes Human genes 0.000 claims abstract description 33
- 238000000855 fermentation Methods 0.000 claims abstract description 23
- 230000004151 fermentation Effects 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims abstract description 10
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 10
- 235000021014 blueberries Nutrition 0.000 claims abstract description 10
- 240000000851 Vaccinium corymbosum Species 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 102000004190 Enzymes Human genes 0.000 claims abstract description 6
- 108090000790 Enzymes Proteins 0.000 claims abstract description 6
- 210000000582 semen Anatomy 0.000 claims description 74
- 241000330899 Hepialus Species 0.000 claims description 39
- 241000190633 Cordyceps Species 0.000 claims description 29
- 240000007594 Oryza sativa Species 0.000 claims description 29
- 235000007164 Oryza sativa Nutrition 0.000 claims description 29
- 235000009566 rice Nutrition 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 11
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 10
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- 240000005440 Corylus heterophylla Species 0.000 claims description 7
- 235000018257 Corylus heterophylla Nutrition 0.000 claims description 7
- 240000000599 Lentinula edodes Species 0.000 claims description 7
- 235000001715 Lentinula edodes Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000012467 final product Substances 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 240000002791 Brassica napus Species 0.000 claims description 3
- 235000011293 Brassica napus Nutrition 0.000 claims description 3
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 claims description 3
- 238000010612 desalination reaction Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 239000004519 grease Substances 0.000 claims description 3
- 230000000474 nursing effect Effects 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 39
- 239000008280 blood Substances 0.000 abstract description 39
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 29
- 239000008103 glucose Substances 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 16
- 239000003925 fat Substances 0.000 abstract description 15
- 230000036039 immunity Effects 0.000 abstract description 13
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 abstract description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 6
- 229920002472 Starch Polymers 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 235000019698 starch Nutrition 0.000 abstract description 5
- 239000008107 starch Substances 0.000 abstract description 5
- 150000001720 carbohydrates Chemical class 0.000 abstract description 3
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 229930195729 fatty acid Natural products 0.000 abstract description 3
- 239000000194 fatty acid Substances 0.000 abstract description 3
- 150000004665 fatty acids Chemical class 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- 241000330896 Thitarodes armoricanus Species 0.000 abstract 2
- 244000017020 Ipomoea batatas Species 0.000 abstract 1
- 235000002678 Ipomoea batatas Nutrition 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- -1 small-molecule amino acids Chemical class 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 19
- 235000019197 fats Nutrition 0.000 description 14
- 230000001093 anti-cancer Effects 0.000 description 11
- 230000037396 body weight Effects 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 230000009182 swimming Effects 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 4
- 238000007872 degassing Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940127003 anti-diabetic drug Drugs 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 235000008935 nutritious Nutrition 0.000 description 3
- 235000014571 nuts Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 239000004382 Amylase Substances 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920005439 Perspex® Polymers 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 244000077233 Vaccinium uliginosum Species 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000003075 phytoestrogen Substances 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical class CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- MJUVRTYWUMPBTR-MRXNPFEDSA-N 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-[1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide Chemical compound FC=1C=C2N(C[C@@H](O)CO)C(C(C)(CO)C)=CC2=CC=1NC(=O)C1(C=2C=C3OC(F)(F)OC3=CC=2)CC1 MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 208000012260 Accidental injury Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical class OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000034699 Vitreous floaters Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010019077 beta-Amylase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N flavone Chemical class O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 210000000196 olfactory nerve Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/02—Preparation of other alcoholic beverages by fermentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供一种以榛子粕为原料酿制的复合榛子酒,同时还公开了其制备工艺,利用冬虫夏草蝙蝠蛾消化酶作为发酵酶制剂,对榛子粕、红薯,蓝莓等原料进行发酵酿造,获得具有提高免疫力抗癌等保健功效的复合榛子酒。采用原料为纯天然中药或药食同源材料,利用它们的协同作用,制成提高免疫力,降血糖血脂,抗癌保健、延缓衰老的功能性榛子酒,产品安全、无副作用,具有显著保健功效,可长期服用,具有很好的市场开发前景;特别是通过冬虫夏草蝙蝠蛾消化酶将榛子中蛋白、淀粉、脂肪类有效分解成小分子氨基酸,糖类,甘油,脂肪酸,有利于下一步发酵酿酒,进一步分解产生大量对人体有益的物质;具有提高免疫力,降血糖血脂,抗癌保健的功效。
Description
技术领域
本发明提供一种以榛子粕为原料酿制的复合榛子酒,同时还公开了其制备工艺,属于保健食品技术领域。
背景技术
榛子营养丰富,榛子仁含脂肪50.6%-63.8%,碳水化合物16.5%,蛋白质16.2-18.0%,膳食纤维8.2%-9.6%,还含有多种维生素,以及抗癌化学成分紫杉醇。目前传统生产坚果保健酒类方法多采用浸泡法,如核桃酒,五味子酒等,由于坚果含油脂类较高,直接采用坚果发酵,酒精及有效成分收率低。而榛子粕是榛子仁脱油后产物,含有丰富的蛋白质、维生素、甾醇等营养成分,但大都被用作动物或植物肥料,经济效益低,资源浪费。
发明内容
本发明提供一种以榛子粕为原料酿制的复合榛子酒,口味醇香、营养丰富,具有提高免疫力和抗癌等保健功效。可以起到保健降血脂、降血糖、抗癌和补充维生素的功效。
本发明还进一步公开了以榛子粕为原料酿制的复合榛子酒的工艺,利用冬虫夏草蝙蝠蛾消化酶作为发酵酶制剂,对榛子粕、红薯,蓝莓等原料进行发酵酿造,获得具有提高免疫力抗癌等保健功效的复合榛子酒。
本发明所述的一种以榛子粕为原料酿造的复合榛子酒,其特征在于主要由以下原料按重量份数比发酵制成的:
榛子粕20~40,榛子叶5~10、蓝莓2-6,豆粕10-20,红薯20-60,猕猴桃根3-8,香菇0.5-1。
本发明所述的一种以榛子粕为原料酿造的复合榛子酒的工艺,包括以下步骤:
按比例称取上述原料,粉碎,加入1-1.5倍重量蒸馏水,均质,高温灭菌,降温至常温,加入重量比0.3-0.5%常规的白酒酒曲,发酵罐常规的发酵,发酵后过滤得澄清滤液,调配即得。
本发明所述的一种以榛子粕为原料酿造的复合榛子酒的工艺,包括以下步骤:
按比例称取上述原料,粉碎,加入1-1.5倍重量蒸馏水,均质,高温灭菌,降温至常温,加入重量比例万分之一至三冬虫夏草蝙蝠蛾消化酶进行酶解,酶解后灭菌,降温,加入重量比0.3-0.5%常规的白酒酒曲,发酵罐常规的发酵,发酵后过滤得澄清滤液,调配即得。
本发明涉及的一种冬虫夏草蝙蝠蛾消化酶的制备方法,包括以下步骤:
1)按榛子粕1份、白萝卜2份、红薯3份、豆粕0.5份的比例配制蝙蝠蛾幼虫饲料,温度5~10℃条件下喂养蝙蝠蛾幼虫(冬虫夏草前体)25~30天;喂养期间对于饲料中的榛子粕按1.0/日的比例逐日增加至25~30份;
2)将步骤1)喂养的蝙蝠蛾幼虫去头剔出虫皮和脂肪取消化道整体,加入10倍磷酸缓冲液4℃低温进行组织匀浆,3000rpm/min离心,取上清液加热到40℃迅速冷却至5℃,过滤除脂肪,透析除盐,冷冻干燥,即得消化酶。
冬虫夏草前体蝙蝠蛾幼虫本身营养丰富,适应寒冷干旱等各种恶劣天气,而食物只是青藏高原产各种植物根茎,其消化酶可以将常规的植物转化为多种营养成分。青藏高原苦寒,植物生长缓慢,植物中营养含量低;由于蝙蝠蛾幼虫消化酶转化率很高,才能生存,所以本发明所述的冬虫夏草蝙蝠蛾消化酶不是冬虫夏草菌种,是活体蝙蝠蛾幼虫经榛子饲养驯化消化酶,是蛋白酶,淀粉酶,脂肪酶等多种消化酶的混合酶、经检测可以将榛子中的蛋白,淀粉,脂肪类有效分解成小分子,有利于下一步发酵酿酒,同时分解产生大量对人体有益的物质。
【用法用量】口服;2次/日;15~20ml/次。
【适应症】免疫力低下、亚健康、高血脂、高血糖、高血压等人群及癌症患者。
本发明的药理药性如下:榛子粕:提油后的副产物是榛子粕;榛子粕还有多种维生素,可以提高免疫力,并且榛子粕中还含有大量不饱和甘油酸,甾醇,具有调节胆固醇,降血脂作用。榛子叶:含有大量黄酮化合物,具有调节血管渗透压的作用。豆粕:大豆含有植物雌激素,而且1克豆腐中含植物雌激素黄豆甙元高达73~97毫克,此种激素可调节身体产生激素,能够起到调节内分泌平衡作用。蓝莓:蓝莓果实含有丰富的营养成分,属高氨基酸、高锌、高钙、高铁、高铜、高维生素的营养保健果品。具有良好的营养保健作用,还具有防止脑神经老化、强心、抗癌、软化血管、增强人的肌体免疫等功能。猕猴桃根:可以清热,利尿,活血,消肿。治肝炎,水肿,跌打损伤,风湿关节痛,淋浊,带下,疮疖,瘰疬。红薯:肿瘤的产生主要是由于上皮细胞的异化,再恶性分裂形成肿瘤。而红薯含有丰富的赖氨酸和β一胡萝卜素,这些都可促使上皮细胞正常成熟,抑制止皮细胞异常分化,消除有致癌作用的氧自由基,阻止致癌物与细胞核中的蛋白质结合,从而达到抗癌的目的。而红薯中含有较多硒,这也是抗癌的原因。香菇:含有的真菌多糖是抗癌活性物质,能促进抗体形成,使机体对肿瘤产生免疫力,抑制肿瘤细胞生长。本发明是依据中医理论基础,利用上述原料协同配伍,相须相使,补血益气、疏肝解郁,健脾降火和血散淤等功效,调理血气、促进血液循环,能活血化瘀,可缓和情绪,调整内分泌;特别是冬虫夏草蝙蝠蛾消化酶可以将榛子粕中的蛋白、淀粉、脂肪类有效分解成小分子,蛋白酶(含有胰蛋白酶,胃蛋白酶,组织蛋白酶等蛋白酶)可以作用于不同氨基酸位点,将大分子蛋白水解成小分子氨基酸和多肽;,淀粉酶(包括α-淀粉酶,β-淀粉酶,γ-淀粉酶等)将长链淀粉水解为葡萄糖、麦芽糖,半乳糖;脂肪酶(磷酸酯酶、固醇酶和羧酸酯酶)可作用于甘油三酯的酯键,使甘油三酯降解为甘油二酯、单甘油酯、甘油和脂肪酸。有利于下一步发酵酿酒,进一步分解产生大量对人体有益的物质,具有提高免疫力,降血糖血脂,抗癌保健的功效。
本发明榛子酒糖尿病小鼠模型实验:
取实验动物:选取昆明级雄性小鼠80只,体重18g±2g随机分成3组;
a正常组(对照组):10只,禁食不禁水12小时,腹腔注射等量柠檬酸缓冲液,每天1次,连续5天。
b模型组10只,禁食不禁水12小时,腹腔注射链脲佐菌素40mg/kg(柠檬酸缓冲液配置)体重,每天1次,连续5天。
C本发明榛子酒(没采用虫冬虫夏草蝙蝠蛾消化酶)10只,禁食不禁水12小时,腹腔注射链脲佐菌素40mg/kg(柠檬酸缓冲液配置)体重,每天1次,连续5天。模型成功后,灌胃给榛子酒2g/kg体重,每天一次,连续10天。
D本发明榛子酒(用冬虫夏草蝙蝠蛾消化酶分解的榛子酒,实施例3)组:10只,禁食不禁水12小时,腹腔注射链脲佐菌素40mg/kg(柠檬酸缓冲液配置)体重,每天1次,连续5天。模型成功后,灌胃给榛子酒2g/kg体重,每天一次,连续10天。
实验结果:血糖的变化
在实验过程中,动态观察了小鼠的血糖的变化。结果显示:造模后,模型组及榛子酒组以及冬虫夏草蝙蝠蛾消化酶酶解的榛子酒小鼠的血糖与正常组小鼠相比显著升高(P<0.001):给药第5天时,加冬虫夏草蝙蝠蛾消化酶和不加冬虫夏草蝙蝠蛾消化酶的榛子酒小鼠血糖都有所降低,但加冬虫夏草蝙蝠蛾消化酶的榛子酒组小鼠血糖降低更多:给药10天时,加冬虫夏草蝙蝠蛾消化酶和不加冬虫夏草蝙蝠蛾消化酶的榛子酒组小鼠血糖比模型组小鼠都明显降低,冬虫夏草蝙蝠蛾消化酶的榛子酒组血糖降低基本正常值(P<0.001)。
结论:本发明榛子酒能降低糖尿病模型小鼠的血糖,从给药5天时血糖开始降低,给药10天时,榛子酒组小鼠的血糖明显低于模型组小鼠;用冬虫夏草蝙蝠蛾消化酶分解的榛子酒比常规的榛子酒更能明显降低血糖。
本发明的抗疲劳实验
材料:选取清洁级成年昆明雄性小鼠120只,18-22g。
抗疲劳实验:120只雄性小鼠以0.5g/(kgd)经口灌胃本发明榛子酒(加蝙蝠蛾消化酶和不加蝙蝠蛾消化酶),对照组用同等重量蒸馏水,连续灌胃30天,去除意外损伤胃小鼠,进行负重游泳试验(各组均16只),爬杆试验(各组均15只)。
负重游泳试验:置小鼠在游泳箱中游泳,水深30cm,水温(25±0.5)℃,鼠尾根部负荷5%体质量的铅皮。记录小鼠子游泳开始至死亡的时间,作为小鼠游泳时间(min)。
爬杆试验:将小鼠放在有机玻璃棒上,使肌肉处于静力紧张状态,记录小鼠由于肌肉疲劳从有机玻璃棒上跌落下来的时间,第3次落水时终止实验,累计3次的时间作为爬杆时间。
表2各组小鼠负重游泳实验、爬杆实验结果
与对照组比较,*P<0.05
榛子酒剂量组小鼠负重游泳时间和爬杆时间较阴性对照组显著延长,加蝙蝠蛾幼虫消化酶榛子酒剂量组比常规的榛子酒剂量组小鼠负重游泳时间和爬杆时间明显延长。
本发明的积极效果在于:所用原料为纯天然中药或药食同源材料,利用它们的协同作用,制成提高免疫力,降血糖血脂,抗癌保健、延缓衰老的功能性榛子酒,产品安全、无副作用,具有显著保健功效,可长期服用,具有很好的市场开发前景;特别是通过冬虫夏草蝙蝠蛾消化酶将榛子中蛋白、淀粉、脂肪类有效分解成小分子氨基酸,糖类,甘油,脂肪酸,有利于下一步发酵酿酒,进一步分解产生大量对人体有益的物质;具有提高免疫力,降血糖血脂,抗癌保健的功效。
具体实施方式:
为使本发明更加容易理解,下面结合具体实施例,进一步阐述本发明。这些实施例只用于说明本发明而不用于限制本发明的范围。
实施例1
冬虫夏草蝙蝠蛾消化酶的制备:
1、按榛子粕1kg、白萝卜2kg、红薯3kg、豆粕0.5kg的比例配制蝙蝠蛾幼虫饲料,温度5~10℃条件下喂养蝙蝠蛾幼虫(冬虫夏草前体)25~30天;喂养期间对于饲料中的榛子粕按1.0kg/日的比例逐日增加至2kg;
2、将步骤1)喂养的蝙蝠蛾幼虫去头剔出虫皮和脂肪取消化道整体,加入10倍磷酸缓冲液匀浆,4℃低温进行组织浆液,3000rpm/min离心,取上清液加热到40℃迅速冷却至5℃,过滤除脂肪,透析除盐,冷冻干燥,即得冬虫夏草蝙蝠蛾消化酶。
实施例2:
称取榛子粕20kg、榛子叶5kg、蓝莓2kg、豆粕10kg、红薯20kg、猕猴桃根3kg、香菇0.5kg混合,粉碎成80目细粉,加入1倍重量蒸馏水,均质,121℃度灭菌,冷却到室温,加入常规的白酒酒曲0.06kg,发酵罐发酵14天,发酵罐除气,硅藻土过滤,滤液即得榛子酒。
实施例3:
榛子粕20kg,榛子叶5kg、蓝莓2kg,豆粕10kg,红薯20kg,猕猴桃根3kg,香菇0.5kg,混合,粉碎,121℃灭菌,冷却到室温,加入实施例1制备的冬虫夏草蝙蝠蛾消化酶0.005kg进行,搅拌均匀,20℃24h,与1倍重量蒸馏水混合,121℃灭菌,冷却到室温,加入常规的白酒酒曲0.25kg,发酵罐发酵14天,发酵罐除气,硅藻土过滤,滤液即得冬虫夏草蝙蝠蛾消化酶的榛子酒。罐装,包装。
实施例4:
榛子粕30kg,榛子叶8kg,蓝莓5kg,豆粕15kg,红薯40kg,猕猴桃根6kg,香菇0.7kg,混合,粉碎,121度灭菌,冷却到室温,加入实施例1准备的冬虫夏草蝙蝠蛾消化酶0.010kg,搅拌均匀,20度24h,与1.5倍量重量蒸馏水混合,121度灭菌,冷却到室温,加入常规的白酒酒曲0.20kg,发酵罐发酵14天,发酵罐除气,硅藻土过滤,滤液即得榛子酒。
实施例5:
榛子粕40kg,榛子叶10kg、蓝莓6kg,豆粕20kg,红薯60kg,猕猴桃根8kg,香菇1kg,混合,粉碎,121度灭菌,冷却到室温,加入实施例1准备的冬虫夏草蝙蝠蛾消化酶0.015kg,搅拌均匀,20度24h,与2倍量体积蒸馏水混合,121度灭菌,冷却到室温,加入常规的白酒酒曲0.15kg,发酵罐发酵14天,发酵罐除气,硅藻土过滤,滤液即得榛子酒。
通过具体临床病例进一步证明本发明榛子酒的疗效:
试用患者100例,其中男性45例,女性55例,均为高血糖高血脂或癌症手术免疫力低下患者,涉及年龄段为21-30岁,31-40岁,41-50岁,51-60岁。根据病情,每次服用本发明15~20ml,每日早、晚二次,两周为一个疗程,连续服用一到两个疗程,并观察治疗效果,在服药期间不服用与其功效相同的滋补品和保健品,其中,有效率:90%;显效率:5%;无效率:5%。
特例举几个典型病例证明本发明的效果:
病例1
某女,47岁自述患糖尿病8年,在医院诊断为2型糖尿病(DM),饮食虽也有控制,但不太严格,每天也抽点时间散步,运动量肯定不够,口服过优降糖、达美康,还用过二甲双胍,最近用拜糖平、诺和龙,但血糖控制始终不理想,空腹血糖都在8-9mmol/L左右。
服用实施例2酿造的榛子酒两个月,患者全身症状明显改善,尿蛋白减少到正常值,血肌酐、尿素氮也有所降低,血脂指标趋向正常值高限,空腹血糖控制在7.0mmol/L左右。
病例2
吴某,男,63岁,退休干部,患糖尿病十余年,长期服西药降糖药治疗,现“三多”症状已不明显。近一年来反复出现下肢水肿,重时按之凹陷没指,甚则行走困难,夜尿频,量少不利,足趾麻木,间有针刺感,伴见畏寒肢冷、气短乏力、精神不振,少言淡漠、腰酸膝软、纳食尚可、舌边齿痕、舌质淡红、苔薄白、脉沉细无力。血压:130/80mmHg,化验检查:尿蛋白++++,24小时尿蛋白定量4.8g,血尿素氮6.50mmol/L,血肌酐180μmmol/l,总胆固醇7.60mmol/l,空腹血糖8.7mmol/L,血清总蛋白70.4mmol/L,白蛋白40.2mmol/L,诊断为2型糖尿病合并糖尿病肾病,服用本实施例3酿造的榛子酒20天症状即见明显改善,随症稍有加减,共服60天,诸症悉除。复查尿蛋白+,血糖6.2mmol/L,血肌酐130μmol/L,
病例3:
某男,80岁,患上前列腺癌晚期骨转移多处,被医院大夫判断时日无多,半个月内消瘦迅速,食欲不振,服用本品实施例4酿造的榛子酒2个星期,一日三餐逐渐恢复,饮食正常,连续服用4个月后,至今已存活1年多,生活正常,癌症未见转移扩散。
病例4:
某女,45岁,确诊为乳腺癌晚期,医生预测只有3个月生命,打算全部金钱进行旅行。旅行中无意发现本品,连续服用实施例5酿造的榛子酒一个月,回到家后到医院检查,所有指标正常,癌细胞全部消失,医生成为奇迹。
病例5:
某男,50岁,烧伤手术后一年,免疫力差,伤口易感染,易高烧,容易疲劳,厌食。当连续服用实施例3酿造的榛子酒两个月后,食欲恢复,免疫力提高未出现伤口感染和高烧等症状,脸色红润有光泽,体质也有明显的提高。
病例6.
张女士,51岁,失眠,睡觉很轻,睡眠时间短整夜做梦,换地方整夜睡不着觉。一天昏昏沉沉,清醒时脑子清楚眼睛睁不开,每天都懒洋洋的,没有精神还伴有高血糖,血脂,便秘,牙齿松动腰痛,服用例48个月后,全部好转,现在每天晚上11点睡到早上7点,有时晚上起夜以后也能马上入睡。血糖、腰腿疼痛症状基本消失。
病例7
某男,56岁,糖尿病,空腹血糖是8-9之间,饭后两小时是11点多,胰导素一天打42个单位。服用例2六个月后之后,小三阳转为阴性,手指甲的竖纹没有了,脚后根皮里肉外的硬块不见了,血糖空腹5.3,饭两小时5.9,胰导素减到一天8个,甘油三酯正常、尿糖正常;血糖下降经过调理血糖一直很稳定,原来可以踢毽子,后因为得病踢不了了,服用本例2两个多月后又可以踢了
病例8
安徽的王先生,63岁,糖尿病6年,之前血压140/85,血糖空腹6.7餐后10.4。服用本例4四个月停掉所有降糖药,7个月后血压110/70,血糖空腹5以下,餐后7左右,全部恢复正常。排便正常、视物清晰、头晕症状消失,
病例9
孙先生,53岁,三高加上糖尿病多种并发症患者,服用本例4治疗,当时空腹血糖7.7,餐后血糖13.8,血压:90-130。经过三个月服用,餐前血糖5.6,餐后血糖8.2,血压:80-120,全部趋于正常。之前双下肢就出现的脬肿,服用本例后不再出现浮肿。心脏原来出现的心缺血,痛感,也都恢复。
病例10.
闫某,63岁,糖尿病、临界高血压、脂肪肝、甘油三酯偏高、服用本品餐前血糖18,餐后25,用胰岛素(长效)早18单位、晚12单位。总感觉身体疲劳、四肢无力,口干、眼睛干涩,偶尔眼前混沌,夜里小腿抽筋胀痛。服用本品例315天,血糖开始下降。20多天开始断续减少胰岛素用量;执行方案一个月药物全部停用,餐前血糖在4.4—7.1之间变化;服用9个月后停掉降糖药和胰岛素,餐前血糖绝大部分在5.5以下服用本例前胆固醇:10.5mmol/L,服用后胆固醇下降至10.5mmol/L。脂肪肝消失,同时体重从175斤下降到140斤。
病例11
张某,身高182cm,体重125kg。失眠,高血压148/98,没有精神,疲劳,飞蚊症,眼睛红,出汗多,肥胖,从小脾胃不好,经常积食,积食后就容易嗓子发炎,咳嗽,发烧,早上总是不停地流清鼻涕,清嗓子,还带有几声咳嗽每天都经受着,体重与失眠和咳嗽的折磨,焦虑,着急,抑郁。服用本例230天后,瘦了4kg,血压正常,晚上睡觉平稳,呼吸顺畅,眼睛清楚多了,没有再出现过积食的情况,抵抗力也明显提高,很少感冒发烧。流清鼻涕。
Claims (4)
1.一种以榛子粕为原料酿造的复合榛子酒,其特征在于主要由以下原料按重量份数比发酵制成的:
榛子粕20~40,榛子叶5~10、蓝莓2-6,豆粕10-20,红薯20-60,猕猴桃根3-8,香菇0.5-1。
2.权利要求书所述的一种以榛子粕为原料酿造的复合榛子酒的工艺,包括以下步骤:
按比例称取上述原料,粉碎,加入1-1.5倍蒸馏水,均质,高温灭菌,降温至常温,加入酒曲酶,发酵罐常规的发酵,发酵后过滤得澄清滤液,调配即得。
3.权利要求1所述的一种以榛子粕为原料酿造的复合榛子酒的工艺,包括以下步骤:
按比例称取上述原料,粉碎,加入1-1.5倍蒸馏水,均质,高温灭菌,降温至常温,加入万分之一至三重量份数的冬虫夏草蝙蝠蛾消化酶进行酶解,酶解后灭菌,降温,加入酒曲酶,发酵罐常规的发酵,发酵后过滤得澄清滤液,调配即得。
4.一种冬虫夏草蝙蝠蛾消化酶的制备方法,包括以下步骤:
1)按榛子粕1份、白萝卜2份、红薯3份、豆粕0.5份的比例配制蝙蝠蛾幼虫饲料,温度5~10℃条件下喂养蝙蝠蛾幼虫(冬虫夏草前体)25~30天;喂养期间对于饲料中的榛子粕按1.0份/日的比例逐日增加至25~30份;
2)将步骤1)喂养的蝙蝠蛾幼虫去头剔出虫皮和脂肪取消化道整体,加入10倍磷酸缓冲液,4℃低温进行组织匀浆,3000rpm/min离心,取上清液加热到40℃迅速冷却至5℃,过滤除脂肪,透析除盐,冷冻干燥,即得消化酶。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610207655.5A CN105733880A (zh) | 2016-04-06 | 2016-04-06 | 一种以榛子粕为原料酿制的复合榛子酒 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610207655.5A CN105733880A (zh) | 2016-04-06 | 2016-04-06 | 一种以榛子粕为原料酿制的复合榛子酒 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105733880A true CN105733880A (zh) | 2016-07-06 |
Family
ID=56253699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610207655.5A Pending CN105733880A (zh) | 2016-04-06 | 2016-04-06 | 一种以榛子粕为原料酿制的复合榛子酒 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105733880A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105695270A (zh) * | 2016-04-06 | 2016-06-22 | 暨南大学 | 一种具有改善睡眠作用的澳洲坚果酒及其生产方法 |
| CN106635705A (zh) * | 2016-12-29 | 2017-05-10 | 广西壮族自治区药用植物园 | 具有奶油清香味的保健酒及其制备方法 |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1336428A (zh) * | 2000-08-02 | 2002-02-20 | 彭辉凤 | 葛根酒 |
| CN101649276A (zh) * | 2009-07-15 | 2010-02-17 | 刘名汉 | 一种花果/蔬蜜酒及其制备方法 |
| CN102260660A (zh) * | 2011-07-05 | 2011-11-30 | 北京师范大学 | 蜂王肠道酶及其制备方法和用途 |
| CN102358878A (zh) * | 2011-10-28 | 2012-02-22 | 江南大学 | 一种用油茶籽粕制酒的方法 |
| CN102550794A (zh) * | 2012-01-06 | 2012-07-11 | 湖北工业大学 | 一种从棉籽粕中提取棉籽蛋白的方法 |
| CN104381011A (zh) * | 2014-09-30 | 2015-03-04 | 中山大学 | 一种冬虫夏草菌种材料的制备及侵染钩蝠蛾幼虫的方法 |
| CN105002038A (zh) * | 2015-06-26 | 2015-10-28 | 刘伟 | 一种牡丹草莓果露酒及其制备方法 |
| CN105087262A (zh) * | 2015-08-24 | 2015-11-25 | 安徽明龙酒业有限公司 | 一种椰味荞麦红枣酒及其制备方法 |
| CN105167013A (zh) * | 2015-09-11 | 2015-12-23 | 吉林省德盛农牧科技发展有限公司 | 一种榛子粕为原料制备的保健食品及工艺 |
| CN105238617A (zh) * | 2015-09-29 | 2016-01-13 | 安徽明龙酒业有限公司 | 菌菇柿叶保健酒及其制备方法 |
-
2016
- 2016-04-06 CN CN201610207655.5A patent/CN105733880A/zh active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1336428A (zh) * | 2000-08-02 | 2002-02-20 | 彭辉凤 | 葛根酒 |
| CN101649276A (zh) * | 2009-07-15 | 2010-02-17 | 刘名汉 | 一种花果/蔬蜜酒及其制备方法 |
| CN102260660A (zh) * | 2011-07-05 | 2011-11-30 | 北京师范大学 | 蜂王肠道酶及其制备方法和用途 |
| CN102358878A (zh) * | 2011-10-28 | 2012-02-22 | 江南大学 | 一种用油茶籽粕制酒的方法 |
| CN102550794A (zh) * | 2012-01-06 | 2012-07-11 | 湖北工业大学 | 一种从棉籽粕中提取棉籽蛋白的方法 |
| CN104381011A (zh) * | 2014-09-30 | 2015-03-04 | 中山大学 | 一种冬虫夏草菌种材料的制备及侵染钩蝠蛾幼虫的方法 |
| CN105002038A (zh) * | 2015-06-26 | 2015-10-28 | 刘伟 | 一种牡丹草莓果露酒及其制备方法 |
| CN105087262A (zh) * | 2015-08-24 | 2015-11-25 | 安徽明龙酒业有限公司 | 一种椰味荞麦红枣酒及其制备方法 |
| CN105167013A (zh) * | 2015-09-11 | 2015-12-23 | 吉林省德盛农牧科技发展有限公司 | 一种榛子粕为原料制备的保健食品及工艺 |
| CN105238617A (zh) * | 2015-09-29 | 2016-01-13 | 安徽明龙酒业有限公司 | 菌菇柿叶保健酒及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 刘莉等: "饲喂四环素和链霉素对贡嘎蝠蛾幼虫生长和肠道消化酶的影响", 《昆虫知识》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105695270A (zh) * | 2016-04-06 | 2016-06-22 | 暨南大学 | 一种具有改善睡眠作用的澳洲坚果酒及其生产方法 |
| CN105695270B (zh) * | 2016-04-06 | 2019-03-22 | 暨南大学 | 一种具有改善睡眠作用的澳洲坚果酒及其生产方法 |
| CN106635705A (zh) * | 2016-12-29 | 2017-05-10 | 广西壮族自治区药用植物园 | 具有奶油清香味的保健酒及其制备方法 |
| CN106635705B (zh) * | 2016-12-29 | 2020-06-30 | 广西壮族自治区药用植物园 | 具有奶油清香味的保健酒及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104322617B (zh) | 一种辅助降血糖的饼干及其制备方法 | |
| CN102907604B (zh) | 一种降糖、降压、减肥、通便养颜、抗疲劳保健品及其生产工艺 | |
| CN103627604B (zh) | 一种益肾保健酒及其制备方法 | |
| CN101822749B (zh) | 治疗高血压高血脂的药物制剂及其制备方法 | |
| CN102940251B (zh) | 一种降血糖降血脂的保健食品 | |
| CN101253903B (zh) | 一种具有减肥功能的保健食品及其制备方法 | |
| CN101579120A (zh) | 一种具有减肥功能的营养食品及其制备方法 | |
| CN104381691A (zh) | 用于预防仔猪营养不良性贫血的功能性饲料及其制备方法 | |
| CN108295211A (zh) | 一种治疗糖尿病的药食同源食品组方及其制备方法 | |
| CN101053621B (zh) | 一种治疗肥胖症的中药组合物及其制备方法 | |
| CN103461585B (zh) | 补气养生中药茶 | |
| KR20130063074A (ko) | 당뇨병과 당뇨합병증의 혈당 혈압 저하작용 조성물 | |
| CN102526456A (zh) | 一种增强免疫力、促进睡眠功能保健药物配方 | |
| CN101773624A (zh) | 一种用于治疗糖尿病的中药组合物及其制备方法 | |
| CN101427720A (zh) | 一种治疗糖尿病的高浓度溶泡茶及其制备方法 | |
| CN105733880A (zh) | 一种以榛子粕为原料酿制的复合榛子酒 | |
| CN107441401A (zh) | 用于降三高的中药组合物及其制备方法 | |
| CN103719864A (zh) | 一种降血糖纳豆组合胶囊及其制备方法 | |
| CN104544084B (zh) | 一种用于糖尿病患者的保健食品 | |
| CN100382832C (zh) | 一种用于改善女性更年期症状的保健食品 | |
| CN103181557A (zh) | 具有减肥功能的营养食品及其制备方法 | |
| CN102552743A (zh) | 一种用于治疗糖尿病的药物组合物及其制备方法 | |
| CN104207121B (zh) | 一种提高免疫力降低三高的食疗保健品 | |
| CN108056461B (zh) | 一种黑木耳润肠功能咀嚼片及其制备方法 | |
| CN104255922A (zh) | 适宜三高人群饮用的保健牛奶及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160706 |